acute myeloid leukemia (AML) | Page 32 | Aplastic Anemia & MDS International Foundation Return to top.

acute myeloid leukemia (AML)

Corey Cutler, MD, MPH, FRCPC

Cutler, Corey
Dana-Farber Cancer Institute

Dr. Cutler received his MD from McGill University, Montreal, Canada. He subsequently received his MPH from the Harvard school of Public Health. He completed postgraduate training in Internal Medicine at Royal Victoria Hospital, Montreal, followed by a fellowship in Hematology/Oncology at DFCI. In 2002, he joined DFCI, where he currently is a member of the Hematologic Malignancies staff.

Andrew Brunner, MD

Brunner, Andrew
Massachusetts General Hospital

Dr. Brunner's clinical area of focus and research projects are focused toward understanding treatment patterns and patient outcomes in MDS and other advanced hematologic malignancies, and to develop new treatments for these patients. The therapies available for patients with MDS have not changed in the last decade, and there is critical need to develop new agents and identify the patients most likely to benefit from a given

Share with